BD Company Repurchases $250M in Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
The company announced it repurchased $250M in BD stock to date in FY26. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorizations in 2021 and 2025. The authorizations provide the company the ability to repurchase shares of its common stock through open market purchases, privately negotiated transactions or other methods.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BDX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 201.920
Low
183.00
Averages
202.38
High
220.00
Current: 201.920
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BD to Host Q1 FY2026 Financial Results Webcast on February 9
- Webcast Announcement: BD will host an audio webcast on February 9, 2026, at 8 a.m. ET to discuss its financial results for Q1 FY2026, providing updates on operations and strategy.
- Financial Release Details: Prior to the call, BD will issue a news release and related presentation materials that will include summary financial information for the quarter ending December 31, 2025, ensuring investors receive timely updates.
- Global Medical Technology Leader: As a leading global medical technology company, BD is committed to advancing health through innovative technologies and solutions that enhance medical discovery, diagnostics, and care delivery, supporting healthcare heroes worldwide.
- Employee and Partner Commitment: With over 70,000 employees, BD is dedicated to improving clinical safety and efficiency while collaborating with organizations globally to tackle some of the most challenging health issues.
Continue Reading
BD and Envetec Collaborate on Sustainable Medical Plastic Recycling
- Recyclability Study: BD and Envetec successfully completed a joint feasibility study indicating that high-quality polymers, such as polystyrene Petri dishes, can be recycled within the medical supply chain, thereby promoting sustainability in the healthcare sector.
- Technological Innovation: Envetec's GENERATIONS® technology transforms regulated medical waste into recyclable polymer flakes through a low-energy chemical disinfection process, marking a significant step towards a circular economy for medical plastics.
- Environmental Impact: This pilot project not only reduces reliance on virgin plastics but also provides sustainable solutions for the healthcare industry to avoid landfilling, facilitating the production of more environmentally friendly medical devices.
- Market Expansion Potential: BD plans to expand the pilot project to process more types of medical plastics using this technology, further promoting the circular use of high-value polymers and enhancing the environmental friendliness of medical devices.
Continue Reading